Trial Profile

Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Mar 2022 Status changed from recruiting to completed.
25 Mar 2022 The primary endpoint Absolute change in DSA strength, titer, and complement fixation is changed to Number of Participants With a Decrease in Titer of One or More DSA, Number of Participants With a Decrease in DSA Titer, and Number of Participants With an Absence of One or More Previously Positive DSA on Cq1 Assay, according to ClinicalTrials.gov.
01 Jul 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com